Application of group LASSO regression based Bayesian networks in risk factors exploration and disease prediction for acute kidney injury in hospitalized patients with hematologic malignancies.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
05 05 2020
Historique:
received: 23 09 2019
accepted: 26 03 2020
entrez: 7 5 2020
pubmed: 7 5 2020
medline: 26 8 2021
Statut: epublish

Résumé

Patients who were diagnosed with hematologic malignancies (HM) had a higher risk of acute kidney injury (AKI). This study applies the Bayesian networks (BNs) to investigate the interrelationships between AKI and its risk factors among HM patients, and to evaluate the predictive and inferential ability of BNs model in different clinical settings. During 2014 and 2015, a total of 2501 inpatients with HM were recruited in this retrospective study conducted in a tertiary hospital, Shanghai of China. Patients' demographics, medical history, clinical and laboratory records on admission were extracted from the electronic medical records. Candidate predictors of AKI were screened in the group-LASSO (gLASSO) regression, and then they were incorporated into BNs analysis for further interrelationship modeling and disease prediction. Of 2395 eligible patients with HM, 370 episodes were diagnosed with AKI (15.4%). Patients with multiple myeloma (24.1%) and leukemia (23.9%) had higher incidences of AKI, followed by lymphoma (13.4%). Screened by the gLASSO regression, variables as age, gender, diabetes, HM category, anti-tumor treatment, hemoglobin, serum creatinine (SCr), the estimated glomerular filtration rate (eGFR), serum uric acid, serum sodium and potassium level were found with significant associations with the occurrence of AKI. Through BNs analysis, age, hemoglobin, eGFR, serum sodium and potassium had directed connections with AKI. HM category and anti-tumor treatment were indirectly linked to AKI via hemoglobin and eGFR, and diabetes was connected with AKI by affecting eGFR level. BNs inferences concluded that when poor eGFR, anemia and hyponatremia occurred simultaneously, the patients' probability of AKI was up to 78.5%. The area under the receiver operating characteristic curve (AUC) of BNs model was 0.835, higher than that in the logistic score model (0.763). It also showed a robust performance in 10-fold cross-validation (AUC: 0.812). Bayesian networks can provide a novel perspective to reveal the intrinsic connections between AKI and its risk factors in HM patients. The BNs predictive model could help us to calculate the probability of AKI at the individual level, and follow the tide of e-alert and big-data realize the early detection of AKI.

Sections du résumé

BACKGROUND
Patients who were diagnosed with hematologic malignancies (HM) had a higher risk of acute kidney injury (AKI). This study applies the Bayesian networks (BNs) to investigate the interrelationships between AKI and its risk factors among HM patients, and to evaluate the predictive and inferential ability of BNs model in different clinical settings.
METHODS
During 2014 and 2015, a total of 2501 inpatients with HM were recruited in this retrospective study conducted in a tertiary hospital, Shanghai of China. Patients' demographics, medical history, clinical and laboratory records on admission were extracted from the electronic medical records. Candidate predictors of AKI were screened in the group-LASSO (gLASSO) regression, and then they were incorporated into BNs analysis for further interrelationship modeling and disease prediction.
RESULTS
Of 2395 eligible patients with HM, 370 episodes were diagnosed with AKI (15.4%). Patients with multiple myeloma (24.1%) and leukemia (23.9%) had higher incidences of AKI, followed by lymphoma (13.4%). Screened by the gLASSO regression, variables as age, gender, diabetes, HM category, anti-tumor treatment, hemoglobin, serum creatinine (SCr), the estimated glomerular filtration rate (eGFR), serum uric acid, serum sodium and potassium level were found with significant associations with the occurrence of AKI. Through BNs analysis, age, hemoglobin, eGFR, serum sodium and potassium had directed connections with AKI. HM category and anti-tumor treatment were indirectly linked to AKI via hemoglobin and eGFR, and diabetes was connected with AKI by affecting eGFR level. BNs inferences concluded that when poor eGFR, anemia and hyponatremia occurred simultaneously, the patients' probability of AKI was up to 78.5%. The area under the receiver operating characteristic curve (AUC) of BNs model was 0.835, higher than that in the logistic score model (0.763). It also showed a robust performance in 10-fold cross-validation (AUC: 0.812).
CONCLUSION
Bayesian networks can provide a novel perspective to reveal the intrinsic connections between AKI and its risk factors in HM patients. The BNs predictive model could help us to calculate the probability of AKI at the individual level, and follow the tide of e-alert and big-data realize the early detection of AKI.

Identifiants

pubmed: 32370757
doi: 10.1186/s12882-020-01786-w
pii: 10.1186/s12882-020-01786-w
pmc: PMC7201633
doi:

Substances chimiques

Hemoglobins 0
Sodium 9NEZ333N27
Potassium RWP5GA015D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

162

Subventions

Organisme : Major Projects of Scientific Research, Innovation Plan of Shanghai Education Commission
ID : no. 2017-01-07-00-07-E00009
Pays : International
Organisme : Shanghai Medical Center of Kidney
ID : no. 2017ZZ01015
Pays : International
Organisme : Zhongshan Hospital Science Foundation for Youths
ID : no.2019ZSQN19
Pays : International

Références

BMC Nephrol. 2017 Jun 24;18(1):203
pubmed: 28646870
Cancer Med. 2019 Jun;8(6):3278-3285
pubmed: 31016881
Blood Purif. 2010;30(2):120-6
pubmed: 20714143
Am J Emerg Med. 2018 Sep;36(9):1650-1654
pubmed: 29970272
Lancet. 2015 Oct 10;386(10002):1465-71
pubmed: 26466051
Nephrol Dial Transplant. 2018 Dec 1;33(12):2218-2227
pubmed: 29846676
Eur J Intern Med. 2011 Aug;22(4):399-406
pubmed: 21767759
Br Med J (Clin Res Ed). 1981 Mar 28;282(6269):1034-5
pubmed: 6783235
Am J Cardiol. 2014 Apr 15;113(8):1331-7
pubmed: 24560063
Kidney Int. 2011 Jul;80(1):17-28
pubmed: 21150873
Can J Diabetes. 2017 Jun;41(3):322-328
pubmed: 28268189
Tohoku J Exp Med. 2015;237(4):287-95
pubmed: 26607258
Sci Rep. 2019 Jul 17;9(1):10376
pubmed: 31316113
Clin J Am Soc Nephrol. 2013 Mar;8(3):347-54
pubmed: 23243268
Contrib Nephrol. 2016;187:1-8
pubmed: 26881802
J Support Oncol. 2011 Jul-Aug;9(4):149-55
pubmed: 21809520
J Cardiothorac Vasc Anesth. 2013 Dec;27(6):1158-66
pubmed: 24050856
MMWR Morb Mortal Wkly Rep. 2018 Mar 16;67(10):289-293
pubmed: 29543788
Kidney Int. 2007 Sep;72(5):624-31
pubmed: 17622275
BMC Pulm Med. 2019 Jan 18;19(1):18
pubmed: 30658615
PLoS One. 2013;8(2):e55870
pubmed: 23457485
Methods Inf Med. 2016 Oct 17;55(5):422-430
pubmed: 27626931
Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1510-8
pubmed: 26231194
Eur J Haematol. 1991 Aug;47(2):119-22
pubmed: 1889480
Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93
pubmed: 23744003
Psychol Med. 2017 May;47(7):1204-1214
pubmed: 28052778
J Am Heart Assoc. 2016 Aug 04;5(8):
pubmed: 27491837
Curr Opin Crit Care. 2015 Dec;21(6):549-58
pubmed: 26539929
J Pediatr Hematol Oncol. 2005 Apr;27(4):202-6
pubmed: 15838391
Comput Methods Programs Biomed. 2016 Apr;126:128-42
pubmed: 26777431

Auteurs

Yang Li (Y)

Department of Nephrology, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Shanghai Medical Center of Kidney, Shanghai, 200032, China.
Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, 200032, China.
Shanghai Institute of Kidney and Dialysis, Shanghai, 200032, China.
Hemodialysis Quality Control Center of Shanghai, Shanghai, 200032, China.

Xiaohong Chen (X)

Department of Nephrology, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Shanghai Medical Center of Kidney, Shanghai, 200032, China.
Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, 200032, China.
Shanghai Institute of Kidney and Dialysis, Shanghai, 200032, China.
Hemodialysis Quality Control Center of Shanghai, Shanghai, 200032, China.

Yimei Wang (Y)

Department of Nephrology, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Shanghai Medical Center of Kidney, Shanghai, 200032, China.
Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, 200032, China.
Shanghai Institute of Kidney and Dialysis, Shanghai, 200032, China.
Hemodialysis Quality Control Center of Shanghai, Shanghai, 200032, China.

Jiachang Hu (J)

Department of Nephrology, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Shanghai Medical Center of Kidney, Shanghai, 200032, China.
Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, 200032, China.
Shanghai Institute of Kidney and Dialysis, Shanghai, 200032, China.
Hemodialysis Quality Control Center of Shanghai, Shanghai, 200032, China.

Ziyan Shen (Z)

Department of Nephrology, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Shanghai Medical Center of Kidney, Shanghai, 200032, China.
Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, 200032, China.
Shanghai Institute of Kidney and Dialysis, Shanghai, 200032, China.
Hemodialysis Quality Control Center of Shanghai, Shanghai, 200032, China.

Xiaoqiang Ding (X)

Department of Nephrology, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Xuhui District, Shanghai, 200032, China. dingxqzshospital@163.com.
Shanghai Medical Center of Kidney, Shanghai, 200032, China. dingxqzshospital@163.com.
Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, 200032, China. dingxqzshospital@163.com.
Shanghai Institute of Kidney and Dialysis, Shanghai, 200032, China. dingxqzshospital@163.com.
Hemodialysis Quality Control Center of Shanghai, Shanghai, 200032, China. dingxqzshospital@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH